Medicamen Biotech Limited (MEDICAMEQ) AI Stock Analysis

• Market Cap: ₹4.41B
• Dividend Yield: 0.27%
• Average Volume (3M): 2.23K
• Price to Earnings (P/E): 49.7
• Beta (1Y): 1.57
• Revenue Growth: -9.90%
• EPS Growth: 33.18%
• Country: IN
• Employees: 378
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.59
• Shares Outstanding: 13,562,815
• 10 Day Avg. Volume: 969
• 30 Day Avg. Volume: 2,233
• PEG Ratio: -2.19
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 3.86
• P/FCF Ratio: -52.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 59 Neutral
• Price Target: ₹339.00 ▲(6.77% Upside)

Medicamen Biotech Limited's overall stock score reflects a combination of mixed financial performance, technical indicators suggesting overbought conditions, and a high valuation. The financial stability is offset by cash flow challenges, while technical analysis indicates potential resistance. The high P/E ratio and low dividend yield suggest limited value and income potential.

Medicamen Biotech Limited Business Overview & Revenue Model

Company Description

Medicamen Biotech Limited (MEDICAMEQ) is a prominent player in the pharmaceutical and biotechnology sectors, specializing in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products including generic medicines, active pharmaceutical ingredients (APIs), and biopharmaceuticals. The company is committed to enhancing healthcare by providing high-quality, cost-effective solutions that cater to various therapeutic areas, including oncology, cardiology, and infectious diseases. With a strong emphasis on innovation and regulatory compliance, MEDICAMEQ aims to improve patient outcomes while expanding its global footprint.

How the Company Makes Money

Medicamen Biotech Limited generates revenue primarily through the sale of its pharmaceutical products, including generics and APIs, to healthcare providers, hospitals, and pharmacies. The company benefits from its extensive product portfolio, which allows it to capture diverse market segments. Key revenue streams include direct sales, contract manufacturing, and strategic partnerships with other pharmaceutical firms for co-development and distribution of products. Additionally, MEDICAMEQ may engage in licensing agreements for its proprietary technologies or formulations, further diversifying its income sources. The company's commitment to research and development enhances its competitive advantage, potentially leading to new product launches that can significantly boost revenue.

Medicamen Biotech Limited Financial Statement Overview

Summary

Medicamen Biotech Limited demonstrates a mixed financial profile. The income statement shows strength in margins, but revenue growth is inconsistent. The balance sheet is solid, enhancing financial stability. However, cash flow challenges, particularly negative free cash flow, could impact liquidity and require strategic adjustments.

Income Statement

Medicamen Biotech Limited has shown a mixed performance in its income statement. The gross profit margin has been moderately strong, but net profit margin has seen some volatility. Revenue growth has been inconsistent, with significant fluctuations year over year. Notably, EBIT and EBITDA margins are relatively healthy, indicating efficient cost management despite variability in revenue.

Balance Sheet

The balance sheet of Medicamen Biotech Limited reflects a stable financial structure. The company maintains a reasonable debt-to-equity ratio, suggesting moderate leverage. The return on equity is satisfactory, reflecting effective use of equity capital. The equity ratio is solid, showing a strong equity position relative to total assets, which is favorable for long-term solvency.

Cash Flow

Medicamen Biotech Limited's cash flow statement reveals challenges, primarily with negative free cash flow over the past years, indicating potential liquidity issues. The operating cash flow to net income ratio is concerning, as operating cash flow has been negative, suggesting difficulties in converting net income into cash. This could pose risks to financial flexibility if it persists.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.63B	1.63B	1.79B	1.41B	1.15B	1.13B
Gross Profit	704.27M	389.90M	852.01M	687.74M	479.88M	335.16M
EBITDA	211.56M	201.02M	245.66M	277.12M	258.07M	204.25M
Net Income	89.48M	71.08M	109.31M	148.44M	148.98M	121.29M
Balance Sheet
Total Assets	0.00	2.97B	2.95B	2.79B	2.26B	1.94B
Cash, Cash Equivalents and Short-Term Investments	37.59M	37.59M	147.86M	207.79M	38.25M	38.91M
Total Debt	0.00	332.53M	311.12M	257.09M	257.96M	188.19M
Total Liabilities	-2.13B	841.04M	875.67M	851.03M	792.24M	611.18M
Stockholders Equity	2.13B	2.13B	2.07B	1.93B	1.46B	1.33B
Cash Flow
Free Cash Flow	0.00	-119.32M	-130.31M	-128.94M	-44.99M	-51.94M
Operating Cash Flow	0.00	-98.59M	-67.44M	-62.93M	41.09M	127.72M
Investing Cash Flow	0.00	-23.78M	-55.63M	-58.80M	-84.73M	-178.13M
Financing Cash Flow	0.00	12.16M	63.13M	291.27M	42.98M	58.39M

Medicamen Biotech Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 317.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Neutral. The current price of 317.5 is above the 20-day moving average (MA) of 311.03, below the 50-day MA of 332.58, and below the 200-day MA of 418.16, indicating a neutral trend. The MACD of -4.68 indicates Negative momentum. The RSI at 53.35 is Neutral, neither overbought nor oversold. The STOCH value of 72.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MEDICAMEQ.

Medicamen Biotech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	69 Neutral	₹6.06B	11.28	―	―	9.15%	88.32%
INDSWFTLAB	66 Neutral	₹7.45B	2.95	―	―	-68.96%	-30.30%
SAKAR	64 Neutral	₹7.72B	39.03	―	―	21.65%	73.16%
MEDICAMEQ	59 Neutral	₹4.41B	49.73	―	0.27%	-9.90%	33.18%
ZIMLAB	56 Neutral	₹3.35B	35.37	―	―	-3.36%	-47.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	43 Neutral	₹3.11B	30.02	―	―	-3.41%	-3028.44%